Effectiveness, immunogenicity and safety of monovalent DS-5670a and bivalent DS-5670a/b SARS-CoV-2 vaccines: results from two randomized, active-comparator, non-inferiority trials

Read full text Summarise with VIRAT
Authors: Shunsuke Hamada, Miharu Suda, Katsuyasu Ishida, Kei Furihata, Yoshitaka Sogawa, Masafumi Kumazaki, Kaori Takahashi, Sachiko Sakakibara, Satoko Matsunaga, Nao Jonai, Tetsuo Nakayama, Fumihiko Takeshita
Cited by: 0
References: 33

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Although the emergency phase of the COVID-19 pandemic is over, attention has remained focused towards ongoing vaccination programs and the protection of high risk populations. The DS-5670 lipid nanoparticle-mRNA vaccine platform contains SARS-CoV-2 spike protein receptor-binding domain (RBD)-derived antigen(s). We conducted studies to provide supporting evidence for DS-5670 as a source of seasonal boosters using RBD antigens from variant strains and different valency compositions. Randomized, active-comparator, non-inferiority studies evaluated monovalent DS-5670a (original strain RBD; Study 146 in 4518 adults ≥18 years) or bivalent DS-5670a/b (original and omicron BA.4-5 RBDs; Study 212 in 701 participants ≥12 years) as boosters. Primary efficacy endpoints were the GMFR in serum neutralization titers against SARS-CoV-2 (original strain) at 4 weeks (day 29) after study drug administration (Study 146), and the GMT and seroresponse rate of anti-SARS-CoV-2 (omicron BA.5 strain) serum neutralization titers on day 29 (Study 212). We show that both studies exceed non-inferiority margins. In Study 146, day 29 adjusted geometric mean fold-rise ratios for DS-5670a are 1.464 (97.5% confidence intervals 1.112, 1.927) vs BNT162b2 and 1.772 (1.335, 2.353) vs mRNA-1273. In Study 212, day 29 adjusted geometric mean titer ratio (DS-5670a/b vs bivalent BNT162b2) is 1.712 (95% confidence intervals, 1.509, 1.944); the between-group difference in seroresponse is 21.4% (13.8, 28.6). Both DS-5670 compositions are effective against symptomatic COVID-19, with broad neutralization activity across omicron sub-lineages. No serious adverse events are associated with DS-5670 in either study. This platform can be utilized to produce new vaccines against future SARS-CoV-2 variants. Initial COVID-19 vaccines, like BNT162b2 and mRNA-1273, used messenger RNA (mRNA) technology and required two doses. However, protection from these vaccines fades over time, and new virus variants pose ongoing health threats. To address this, seasonal booster vaccines are being developed. Here, we develop two different versions of the DS-5670 vaccine and test their performance as boosters in Japan, and compared with existing COVID-19 vaccines. Both versions of DS5670 were able to produce good immune responses against various SARS-CoV-2 strains and were at least as effective as existing vaccines. Our findings indicate that DS-5670 could serve as an effective seasonal booster, with potential for future adaptation to emerging strains. Hamada et al., evaluated the efficacy, immunogenicity and safety of monovalent and bivalent lipid nanoparticle-mRNA vaccine, DS-5670, against SARS-CoV-2 variants in two randomized trials. Findings show DS-5670 is as effective as existing mRNA vaccines, with broad neutralization activity across omicron sub-lineages.

Fields of Study & Subjects

SARS-CoV-2 and COVID-19 Research Vaccine Coverage and Hesitancy COVID-19 Clinical Research Studies

Publication details

Journal / source
Communications Medicine
Volume
6
Issue
1
Pages
320
Publication date
31 March 2026
Language
EN